PremiumMarket NewsChemoCentryx Q3 Results Surpass Expectations; Street Says Buy ChemoCentryx Stock: Worth Keeping an Eye on 3 ‘Strong Buy’ Stocks Raymond James Predicts Will Rally Over 60% PremiumMarket NewsChemoCentryx Releases Avacopan Trial Results For Rare Kidney Disease; Shares Plunge 8% 3 “Perfect 10” Healthcare Stocks That Have Plenty of Growth on Tap